#1 Clinical Trials Search in Europe

Nivolumab

Nivolumab, also known by its brand name Opdivo, is an immunotherapy drug being studied in various clinical trials for treating different types of cancer. These trials aim to evaluate the safety and effectiveness of nivolumab alone or in combination with other treatments for conditions like melanoma, lung cancer, lymphoma, and more. Researchers are exploring nivolumab’s potential to boost the immune system’s ability to fight cancer and improve outcomes for patients.

Table of Contents

What is Nivolumab?

Nivolumab, also known by its brand name Opdivo, is a type of immunotherapy drug used to treat various types of cancer[2][6]. It belongs to a class of medications called immune checkpoint inhibitors, which work by helping your body’s immune system fight cancer cells[8].

How Nivolumab Works

Nivolumab works by targeting a protein called PD-1 (Programmed Death-1) that is found on immune cells. In normal circumstances, PD-1 acts as a “brake” on the immune system to prevent it from attacking healthy cells. However, some cancer cells can exploit this mechanism to evade the immune system. Nivolumab blocks PD-1, effectively “releasing the brakes” on the immune system and allowing it to recognize and attack cancer cells more effectively[1][6].

Conditions Treated with Nivolumab

Nivolumab has been approved to treat several types of cancer, including:

  • Melanoma: A type of skin cancer[3]
  • Non-small cell lung cancer[2]
  • Head and neck squamous cell carcinoma (HNSCC): A type of cancer that affects the mouth, nose, and throat[6]
  • Urothelial cancer: A type of bladder cancer[7]
  • Hodgkin lymphoma: A cancer of the lymphatic system[5]
  • Colorectal cancer (in specific cases)[8]

Researchers are also exploring its use in other types of cancers and conditions.

How Nivolumab is Administered

Nivolumab is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific condition being treated and individual patient factors. Common dosing schedules include:

  • 240 mg every 2 weeks[6]
  • 480 mg every 4 weeks[7]
  • 3 mg/kg (milligrams per kilogram of body weight) every 2 weeks[5]

Treatment duration can vary, but it may continue for up to two years or until the disease progresses or unacceptable side effects occur[4].

Nivolumab in Combination Therapies

Nivolumab is often used in combination with other treatments to enhance its effectiveness. Some common combinations include:

  • Nivolumab + Ipilimumab: Ipilimumab is another immunotherapy drug that targets a different immune checkpoint (CTLA-4). This combination is used in various cancers, including melanoma and colorectal cancer[4][7].
  • Nivolumab + Chemotherapy: Combining nivolumab with traditional chemotherapy drugs can sometimes improve outcomes in certain cancers[3].
  • Nivolumab + Radiotherapy: Some studies are exploring the combination of nivolumab with low-dose radiation therapy to enhance the immune response against cancer[5].

Potential Side Effects

As with any medication, nivolumab can cause side effects. Because it works by stimulating the immune system, many side effects are related to an overactive immune response. Common side effects may include:

  • Fatigue
  • Skin rash or itching
  • Diarrhea
  • Nausea
  • Decreased appetite

More serious side effects, though less common, can include inflammation in various organs such as the lungs, liver, or thyroid gland. It’s important to report any new symptoms to your healthcare provider promptly[6].

Ongoing Research and Future Directions

Researchers continue to study nivolumab to understand how to use it most effectively. Some areas of ongoing research include:

  • Biomarkers for response: Scientists are trying to identify characteristics in patients or tumors that can predict who will respond best to nivolumab treatment[6].
  • Novel combinations: Studies are exploring new combinations of nivolumab with other treatments, such as targeted therapies or novel immunotherapies[9].
  • Expanding indications: Researchers are investigating nivolumab’s effectiveness in additional types of cancers and at different stages of disease[10].
  • Overcoming resistance: Some studies are looking at ways to make tumors that don’t initially respond to nivolumab more susceptible to treatment[8].

As research progresses, our understanding of how to use nivolumab most effectively continues to grow, offering hope for improved outcomes for cancer patients.

Aspect Details
Drug Name Nivolumab (Opdivo)
Type of Treatment Immunotherapy
Mechanism of Action Blocks PD-1 protein on immune cells
Cancer Types Studied Melanoma, lung cancer, lymphoma, liver cancer, head and neck cancer
Administration Intravenous infusion every 2-4 weeks
Common Side Effects Fatigue, skin rash, diarrhea, nausea
Treatment Duration Varies, often up to 1-2 years in trials
Key Outcomes Measured Overall survival, progression-free survival, response rate, safety

FAQ

  • What is nivolumab and how does it work? Nivolumab is an immunotherapy drug that helps the immune system fight cancer. It works by blocking a protein called PD-1 on immune cells, which allows them to better recognize and attack cancer cells.
  • What types of cancer is nivolumab being studied for? Clinical trials are evaluating nivolumab for various cancers including melanoma, non-small cell lung cancer, follicular lymphoma, hepatocellular carcinoma, and head and neck cancers, among others.
  • How is nivolumab administered in clinical trials? In most trials, nivolumab is given as an intravenous infusion every 2-4 weeks. The exact dose and schedule can vary between studies.
  • What are some potential side effects of nivolumab? Common side effects may include fatigue, skin rash, diarrhea, and nausea. More serious immune-related side effects can occur but are less common. Trials closely monitor patients for any adverse events.
  • How long do patients typically receive nivolumab in clinical trials? The duration of treatment varies between trials, but many studies continue nivolumab for up to 1-2 years or until disease progression or unacceptable toxicity occurs.

Ongoing Clinical Trials on Nivolumab

  • A Study Comparing MB11 and Nivolumab in Adults With Previously Untreated Advanced or Metastatic Melanoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Greece Italy Poland Portugal Romania Slovakia +1

  • Study of ipilimumab and nivolumab injected into tumors before surgery in patients with stage III melanoma that can be removed by surgery

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

    Recruiting

    1 1
    Investigated drugs:
    Germany Italy Poland Romania Spain

  • A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Romania Spain

  • A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

    Recruiting

    1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study of Heart and Blood Vessel Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Drug Combination Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

  • Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark France Germany Greece +6

  • Study of intraperitoneal paclitaxel combined with systemic therapy versus systemic therapy alone for patients with gastric cancer and peritoneal metastases

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands Norway Sweden

  • Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy Poland Romania

Glossary

  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
  • PD-1: A protein on immune cells that nivolumab targets to help the immune system recognize and attack cancer cells.
  • Intravenous infusion: A method of giving medicine directly into a vein using a needle or tube.
  • Adverse events: Unwanted or harmful effects that may occur during treatment.
  • Disease progression: When cancer continues to grow or spread despite treatment.
  • Overall survival: The length of time from the start of treatment until death from any cause.
  • Progression-free survival: The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • RECIST criteria: A standard way to measure how well a cancer patient responds to treatment.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor.
  • Adjuvant therapy: Additional treatment given after the main treatment to lower the risk of cancer coming back.

References

  1. https://clinicaltrials.gov/study/NCT04413838
  2. https://clinicaltrials.eu/trial/study-on-heart-function-changes-in-cancer-patients-treated-with-nivolumab-or-pembrolizumab/
  3. https://clinicaltrials.gov/study/NCT03982121
  4. https://clinicaltrials.gov/study/NCT05407441
  5. https://clinicaltrials.gov/study/NCT03495713
  6. https://clinicaltrials.gov/study/NCT03652142
  7. https://clinicaltrials.gov/study/NCT05219435
  8. https://clinicaltrials.gov/study/NCT03832621
  9. https://clinicaltrials.gov/study/NCT05385263
  10. https://clinicaltrials.gov/study/NCT03886311